company background image
REGN logo

Regeneron Pharmaceuticals NasdaqGS:REGN Stock Report

Last Price

US$922.79

Market Cap

US$100.1b

7D

-2.0%

1Y

16.6%

Updated

30 Oct, 2024

Data

Company Financials +

Regeneron Pharmaceuticals, Inc.

NasdaqGS:REGN Stock Report

Market Cap: US$100.1b

REGN Stock Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

REGN fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance3/6
Financial Health5/6
Dividends0/6

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

US$1.13k
FV
18.6% undervalued intrinsic discount
8.10%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Updated narrative

Regeneron Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Regeneron Pharmaceuticals
Historical stock prices
Current Share PriceUS$922.79
52 Week HighUS$1,211.20
52 Week LowUS$774.98
Beta0.12
11 Month Change-12.22%
3 Month Change-15.58%
1 Year Change16.62%
33 Year Change41.51%
5 Year Change184.38%
Change since IPO4,268.24%

Recent News & Updates

Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors

Sep 25

Recent updates

Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors

Sep 25

Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Sep 09
Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Regeneron Stock: Valuation Now Demands More Growth

Aug 26

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price

Aug 22
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price

Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Aug 04
Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Regeneron's Robust Pipeline And Financial Health Signal Continued Growth

Aug 02

Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings

Jul 11

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

Jun 08
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

May 21
These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks

May 06

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Apr 30
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Apr 10
Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate

Mar 26

Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Feb 16
Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024

Feb 10

Regeneron's Push Into Obesity, Q4 2023 Earnings Review

Feb 02

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Jan 31
These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Shareholder Returns

REGNUS BiotechsUS Market
7D-2.0%0.5%0.5%
1Y16.6%24.7%36.8%

Return vs Industry: REGN underperformed the US Biotechs industry which returned 24.7% over the past year.

Return vs Market: REGN underperformed the US Market which returned 36.8% over the past year.

Price Volatility

Is REGN's price volatile compared to industry and market?
REGN volatility
REGN Average Weekly Movement3.3%
Biotechs Industry Average Movement9.6%
Market Average Movement6.1%
10% most volatile stocks in US Market15.0%
10% least volatile stocks in US Market3.0%

Stable Share Price: REGN has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: REGN's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198813,926Leonard Schleiferwww.regeneron.com

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.

Regeneron Pharmaceuticals, Inc. Fundamentals Summary

How do Regeneron Pharmaceuticals's earnings and revenue compare to its market cap?
REGN fundamental statistics
Market capUS$100.09b
Earnings (TTM)US$4.32b
Revenue (TTM)US$13.49b

23.0x

P/E Ratio

7.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
REGN income statement (TTM)
RevenueUS$13.49b
Cost of RevenueUS$6.30b
Gross ProfitUS$7.19b
Other ExpensesUS$2.86b
EarningsUS$4.32b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Oct 31, 2024

Earnings per share (EPS)40.04
Gross Margin53.27%
Net Profit Margin32.04%
Debt/Equity Ratio7.0%

How did REGN perform over the long term?

See historical performance and comparison